[Prevalence of human immunodeficiency virus (HIV)-Trypanosoma cruzi co-infection and injectable-drugs abuse in a Buenos Aires health center].
The aim of this study was to evaluate the prevalence of human immunodeficiency virus (HIV)-Trypanosoma cruzi co-infection in a Buenos Aires health center. A retrospective analysis of the clinical charts of 602 HIV-infected patients was performed. Only 51.3% of the patients were evaluated against T. cruzi. The global co-infection prevalence was 4.2%, being more frequent among injectable drug users (IDU) (8.9% vs. 2.6%, < 0.05). The indication of T. cruzi testing should be stressed for HIV-infected patients, especially in those centers where IDU are assisted.
Dolcini
G
G
Centro Nacional de Referencia para el SIDA, Departamento de Microbiología, Parasitología e Inmunología, Universidad de Buenos Aires, Paraguay 2155 Piso 11 (1121) Ciudad Autónoma de Buenos Aires, Argentina. gdolcini@fmed.uba.ar
Ambrosioni
J
J
Andreani
G
G
Pando
M A
MA
Martínez Peralta
L
L
Benetucci
J
J
D001118:Argentina; D014355:Chagas Disease / Q000150:complications* / Q000453:epidemiology*; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology*; D006801:Humans; D008297:Male; D015995:Prevalence; D012189:Retrospective Studies; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000453:epidemiology*